Abstract
Purpose
Few studies have estimated population prevalence and morbidity of primary immunodeficiency diseases (PIDD). We used administrative healthcare databases to estimate the prevalence of PIDD diagnoses in the United States from 2001 to 2007.
Methods
MarketScan databases compile claims from commercial health insurance plans and Medicaid, recording individual diagnoses for outpatient encounters and hospital stays. We used a cross sectional survey to estimate prevalence of PIDD using related ICD-9 codes (279.0, 279.1, 279.2, 279.8, 279.9, 288.1 and 288.2). Persons with secondary immunodeficiency diagnoses were excluded from analysis.
Results
Between 2001 and 2007, prevalence of any PIDD diagnosis increased from 38.9 to 50.5 per 100,000 among privately insured and from 29.1 to 41.1 per 100,000 among publicly insured persons. B cell defects predominated. Prevalence was more than twice as high among Whites as among Blacks or Hispanics.
Conclusion
In this large database, we found a higher prevalence of diagnosed PIDD than has been reported previously from registries. Increased awareness may have contributed to the increasing prevalence.
Similar content being viewed by others
References
Stadtmauer G, Cunningham-Rundles C. Outcome analysis and cost assessment in immunologic disorders. JAMA. 1997;278(22):2018–23.
Baumgart KW, Britton WJ, Kemp A, et al. The spectrum of primary immunodeficiency disorders in Australia. J Allergy Clin Immunol. 1997;100:415–23.
Eades-Perner AM, Gathmann B, Knerr V, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2004–06. Clin Exp Immunol. 2007;147(2):306–12.
Fasth A. Primary immunodeficiency disorders in Sweden: cases among children, 1974–1979. J Clin Immunol. 1982;2:86–92.
Gathmann B, Grimbacher B, Beauté J, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006–2008. Clin Exp Immunol. 2009;157:3–11.
Geller-Bernstein C, Etzioni A. Pediatric allergy and immunology in Israel. Ped All Immunol. 2013;24:187–94.
Ishimura M, Takada H, Doi T, et al. Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol. 2011;31(6):968–76.
Kirkpatrick P, Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol. 2007;27(5):517–24.
Lee WI, Huang JL, Jaing TH, et al. Distribution, clinical features and treatment in Taiwanese patients with symptomatic primary immunodeficiencies (PIDs) in a nationwide population based study during 1985–2010. Immunobiology. 2011;216(12):1286–94.
Stray-Pedersen A, Abrahamsen TG, Frøland SS. Primary immunodeficiency diseases in Norway. J Clin Immunol. 2006;20(6):477–85.
Joshi AY, Iyer VN, Hagan JB, et al. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16–22.
Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497–502.
CEREDIH: The French PID study group. The French national registry of primary immunodeficiency diseases. Clin Immunol. 2010;135(2):264–72.
Leiva LZ, Zelazco M, Oleastro M, et al. Primary immunodeficiency diseases in Latin america: the second report of the LAGID registry. J Clin Immunol. 1997;27:101–8.
Winkelstein JA, Marino MC, Johnston RB, et al. Chronic granulomatous disease: a report on a national registry of 368 patients. Medicine. 2000;79(3):155–69.
Winkelstein JA, Marino MC, Ochs H, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine. 2003;82:373–84.
Winkelstein JA, Marino M, Lederman H, et al. X-linked agammaglobulinemia: report on a united states registry of 201 patients. Medicine. 2006;85:193–207.
Yarmohammadi H, Estrella L, Doucette J, Cunningham-Rundles C. Recognizing primary immunodeficiencies in clinical practice. Clin Vacc Immunol. 2006;13:329–32.
Edgar JDM, Buckland M, Guzman D, et al. The United Kingdom primary immune deficiency (IKPID) registry: report of the first 4 years’ activity 2008–2012. Clin Exp Immunol. 2013;175:68–78.
Bousfiha AA, Jeddane L, Ailal F, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immun. 2013;33:1–7.
Baker MW, Laessig RH, Katcher ML, et al. Implementing routine testing for severe combined immunodeficiency within Wisconsin’s newborn screening program. Public Health Rep. 2010;125(S2):88–95.
Gerstel-Thompson JL, Wilkey JF, Baptiste JC, et al. High-throughput multiplexed T-cell-receptor excision circle quantitative PCR assay with internal controls for detection of Severe Combined Immunodeficiency in population based newborn screening. Clin Chem. 2010;56(9):1466–74.
Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the united states. JAMA. 2014;312(7):729–38.
U.S. Census Bureau. Profile of general demographic characteristics: 2005. http://www.census.gov/popest/datasets/demographic_profile/0_United_States/2kh00.pdf, Accessed August 10, 2014.
Gathmann B, Goldacker S, Klima M, et al. German national registry for primary immunodeficiencies (PID). Clin Exp Immunol. 2013;173(2):372–80.
Champi C. Primary immunodeficiency disorders in children: prompt diagnosis can lead to lifesaving treatment. J Pediatr Health Care. 2003;16(1):6–21.
Cunningham-Rundles C, Bodian L. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.
Lindegren ML, Kobrynski L, Rasmussen S, et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm Rep. 2004;53(RR-1):1–29.
Waltenburg R, Kobrynski L, Reyes M, Bowen S, Khoury MJ. Primary immunodeficiency diseases: practice and awareness among the general public, United States, 2008. Genet Med. 2010;12:792–800.
AAP position statement. The changing concept of sudden infant death syndrome: diagnostic coding shifts, controversies regarding the sleeping environment, and new variables to consider in reducing risk. Pediatr. 2005;116(5):1245–55.
de Vries E, the European Society for Immunodeficiencies (ESID) members. Patient-centered screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. Clin Exp Immunol. 2011;167:108–19.
Cunningham-Rundles C. Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol. 1989;9(1):22–33.
Buckley RH. Variable phenotypic expression of mutations in genes of the immune system. J Clin Invest. 2005;115:2974.
Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haematopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet. 2003;361(9357):553–60.
Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99(3):872–8.
Pai S, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med. 2014;371:434–46.
Resnick ES, Bhatt P, Sidi P, Cunningham-Rundles C. Examining the use of ICD-9 diagnosis codes for primary immune deficiency diseases in New York state. J Clin Immunol. 2013;33:40–8.
Cunningham-Rundles C, Sidi P, Estrella L, Doucette J. Identifying undiagnosed primary immunodeficiency diseases in minority subjects using computer sorting of diagnosis codes. J Allergy Clin Immunol. 2004;113:747–56.
Kwan A, Church J, Cowan M, et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol. 2013;132:140–50.
Vogel B, Bonagura V, Weinberg GA. Newborn screening for SCID in New York state: experience from the first 2 years. J Clin Immunol. 2014;34:289–303.
Park M, Li J, Hagan J, Maddox D, Abraham R. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008;372:489–502.
Acknowledgments
This research was supported in part by an appointment (RWP) to the Research Participation Program at the CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. Thanks to the Jeffrey Modell Foundation for promoting awareness of Primary Immune Deficiencies.
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Rights and permissions
About this article
Cite this article
Kobrynski, L., Powell, R.W. & Bowen, S. Prevalence and Morbidity of Primary Immunodeficiency Diseases, United States 2001–2007. J Clin Immunol 34, 954–961 (2014). https://doi.org/10.1007/s10875-014-0102-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-014-0102-8